CD79B and diffuse large B-cell lymphoma: In 21–25% of ABC-DLBCL, activating CD79B mutations provide proximal enhancement of BCR-mediated signaling but do not initiate BCR signaling themselves (Davis et al., 2010; Reddy et al., 2017; Schmitz et al., 2018; Wilson et al., 2015).